Glycated Hemoglobin In The Screening And Diagnosis Of Renal Post-transplantation Diabetes | 35460
Journal of Nephrology & Therapeutics
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Post-transplantation diabetes mellitus (PTDM) is a glucose metabolism alteration with high incidence during the first year after
renal transplantation. It is associated with adverse outcomes, as graft rejection and cardiovascular disease. Available data in the
literature show that, in renal transplant patients, the oral glucose tolerance test (OGTT) presents the highest diagnostic sensitivity for
PTDM, although fasting plasma glucose (FPG) is the most requested test. Glycated hemoglobin (HbA1c) has been used in clinical
practice for the monitoring of diabetes for more than 20 years. Since 2010, it has also been applied as a diagnostic test, with cut-off
point of 6.5%. However, there are still controversies about the applicability of HbA1c results to detect PTDM. For now, OGTT should
remain the reference test for PTDM once there is still no consensus on what HbA1c threshold to be applied for the screening and
diagnosis of PTDM. The use of an algorithm with HbA1c test in combination with FPG and/or 2 h-plasma glucose after an OGTT
seems to be an efficient strategy to diagnose or rule out PTDM in the early period after renal transplantation. The use of HbA1c cutoff
points of ≥6.2% to rule in and ≤5.8% to rule out PTDM would reduce the number of OGTT in 85%.
Ana Laura Pimentel is a PhD Candidate in Medical Sciences (Endocrinology) at Federal University of Rio Grande do Sul State (UFRGS, Brazil). She earned her MS in Medical Sciences (Endocrinology) from UFRGS. She is a pharmacist and has been working in the fields of diagnostic test accuracy, diabetes mellitus and renal transplantation.